In competing risk analysis, death from lung cancer was similar between groups (2.9% vs. 4.2%, p = 0.3), whereas death from other causes was significantly higher in the ILA group (13.0% vs. 3.7%, p < 0.001). Here, TNFRSF9 is linked to lung carcinoma.